TumorBoardTuesdayThank you to @jessrzanotti & @RachelRiechelm2 for an exceptional #TumorBoardTuesday on hypermutation in #NET- how might this change care in the future?
Check out thread below & answer the question at the end to get free #CME!
Special edition of Case Wrap Up drops tomorrow!💡
---
RT @jessrzanotti
@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_…
https://twitter.com/jessrzanotti/status/1653555761094557697
Jéssica Zanotti on Twitter
“@TumorBoardTues @RachelRiechelm2 @MPishvaian @JohnEbbenMDPhD @PamelaKunzMD @marklewismd @DianeReidyLagun @timpawlik @CanHealeu @duiliorocha_onc @RenataDAlpino @DBulzico @Juanmaoconnor @Nanodioca @OncoThor @helops79 @rcarvalhoonco @donadio_ds @leogilsan @ManikAmin4 @chirayumohin @carlacav @realbowtiedoc @jaypsv @viniciu_antonio @letswinpc 6/15 #TumorBoardTuesday 👩🏻🏫Mini tweetorial 2👩🏻🏫 📌MSI biomarker 📍≤ 10% of neuroendocrine carcinoma 📍MSI & TMB-h rare in G3 (<1%) 📍Hypermutation may be induced by temozolamide in #gliomas and #NETCancer 📍Molecular profiling upon DP on alkylating agents may find TMB-h”